Tracheal cancer – treatment results, prognostic factors and incidence of other neoplasms
, and | Sep 08, 2016
About this article
Article Category: Research Article
Published Online: Sep 08, 2016
Page range: 409 - 417
Received: Jan 29, 2016
Accepted: Jun 16, 2016
DOI: https://doi.org/10.1515/raon-2016-0046
© 2016 Radiol Oncol
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Distribution of histology types and methods of treatment summary
| Number of patients | |
|---|---|
| Squamous cell carcinoma | 37 (63.8%) |
| Adenoid cystic carcinoma | 9 (15.5%) |
| Microcellular carcinoma | 5 (8.6%) |
| Non-microcellular carcinoma | 4 (6.9%) |
| Adenocarcinoma | 2 (3.5%) |
| Papillary carcinoma | 1 (1.7%) |
| Radiotherapy | 25 |
| Radiotherapy + endoscopic resection | 10 |
| Radiotherapy + surgery | 4 |
| Radiotherapy + chemotherapy | 6 |
| Radiotherapy + endoscopic resection | |
| + chemotherapy | 3 |
| Endoscopic resection | 3 |
| Chemotherapy | 5 |
| Symptomatic | 2 |
The characteristics of radiotherapy
| Number of patients | Total dose range (Gy2) | Median total dose (Gy2) | Mean total dose (Gy2) | SD (Gy2) | Fraction dose (Gy) | Median fraction dose (Gy) | Mean fraction dose (Gy) | |
|---|---|---|---|---|---|---|---|---|
| Radiotherapy | 48 | 14.0–82.6 | 33.2 | 45.0 | ±21.5 | 1.6–8.0 | 2.5 | 3.0 |
| 23 | ||||||||
| External beam | 23 | 42.5–82.6 | 66.0 | 66.4 | ±8.8 | 1.6–3.0 | 2.0 | 2.0 |
| radiotherapy | ||||||||
| Brachytherapy boost | 3 | 12.5–16.0 | 16.0 | 14.8 | ±2.0 | 5.0–6.0 | 6.0 | 5.6 |
| 24 | 18.7–48.5 | 24.0 | 28.2 | ±7.4 | 2.0–8.0 | 4.0 | 3.7 | |
| External beam | ||||||||
| radiotherapy | 20 | 18.7–42.0 | 23.3 | 27.1 | ±5.7 | 2.0–4.0 | 4.0 | 3.4 |
| Brachytherapy | ||||||||
| 5 | 16.0–29.7 | 24.0 | 23.5 | ±4.9 | 6.0–8.0 | 6.0 | 6.6 |
The characteristics of other cancers among patients with tracheal cancer (TC)
| Patient No | HP of TC | Year of diagnosis of TC | HP of the other cancer | Year of diagnosis of the other cancer |
|---|---|---|---|---|
| (1) | SCC | 2011 | Myelodysplastic syndrome | 2009 |
| (2) | SCC | 2006 | Larynx cancer - SCC | 1998 |
| (3) | SCC | 2005 | Clear cell renal carcinoma | 2005 |
| (4) | SCC | 2011 | Thyroid adenocarcinoma | 1978 |
| (5) | ACC | 2005 | Lung cancer - SCC | 2006 |
| (6) | Non-micro | 2013 | Clear cell renal carcinoma | 1995 |
| (7) | SCC | 2008 | Larynx cancer - SCC | 1999 |
| (8) | SCC | 1999 | Lung cancer - SCC | 1995 |
| (9) | SCC | 2003 | Larynx cancer - SCC | 2000 |
| (10) | Micro | 2010 | Prostate cancer - adenocarcinoma | 2008 |
| (11) | SCC | 2015 | Breast cancer - mucinous carcinoma | 2005 |